New blinded data from ~45 patients to date in key pain and function scales and safety and tolerability of the Company’s proprietary ...

In a large randomized trial, treating patients with acute hypoxemic respiratory failure with high-flow oxygen didn't improve ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A Virginia-based biotech company has announced dosing of ...

Data are needed on the effect of oxygen delivered through a high-flow nasal cannula, as compared with standard oxygen therapy, on intubation and mortality in patients with acute hypoxemic ...

NORFOLK, Va.--(BUSINESS WIRE)--ReAlta Life Sciences (“ReAlta”), Inc., a clinical mid-stage biotech company dedicated to addressing life-threatening rare diseases by harnessing the power of the immune ...

In a recent study published in Respiratory Medicine, researchers reported that silent hypoxia was not unique to coronavirus disease 2019 (COVID-19). Silent hypoxemia syndrome, well-tolerated hypoxemia ...

The combination of a vascular endothelial growth factor (VEGF) –neutralizing antibody, bevacizumab, and irinotecan is associated with high radiographic response rates and improved survival outcomes in ...